PI

SPONSOR

GRANT #

START

STOP

Total Awarded to Date

TITLE

SCHWIEBERT, ERIK M

UAB-SRI JOINT RESEARCH PROJECT INITIATIVE

______

01/05/04

01/04/06

$100,000

Fluorescence-Based High Throughput Screening for Novel Calcium Entry Ligands to Control Human Disease: Novel Therapeutics for Cystic Fibrosis and Diabetes Mellitus

JI, HONG-LONG

CYSTIC FIBROSIS FOUNDATION

JI04GO

09/01/04

03/31/06

$113,085

Interactions of CFTR and Proton-Gated Na Channels

CLANCY, JOHN PAUL

NIH-NHLBI

R01HL67088

05/03/01

04/30/06

$1,020,400

Regulation of CFTR by Adenosine, A2 Receptors, and PLA2

SCHWIEBERT, ERIK M

CYSTIC FIBROSIS FOUNDATION

SCHWIE05P0

05/01/05

04/30/06

$75,000

Epithelial Zinc Receptors and Rescue of Respiratory CF

ROWE, STEVEN M

CYSTIC FIBROSIS FOUNDATION

ROWE05D0

01/01/06

06/30/06

$26,597

Suppression of Premature Stop Mutations in CFTR

MATALON, SADIS

NIH-NHLBI

R01HL072871

09/30/02

07/31/06

$1,248,500

Modulation of Innate Immunity in Lung Transplantation (includes studies of CF individuals)

DELUCAS, LAWRENCE J.

CYSTIC FIBROSIS FOUNDATION

DELUCA03GO

01/01/04

11/30/06

$453,017

Production of full-length CFTR Proteins

CLANCY, JOHN PAUL

THE RESEARCH INSTITUTE (TRI) CHILDREN'S HOSPITAL BIRMINGHAM

______

01/01/05

12/31/06

$100,000

Matrix Metalloproteinases in Cystic Fibrosis Lung Disease

CLANCY, JOHN PAUL

CYSTIC FIBROSIS SERVICES, INC. / CHILDREN'S HOSPITAL & REGIONAL MEDICAL CENTER

OM003 (SCHEDULE 2.0)

02/01/04

12/31/06

$39,300

Assessment of Induced Sputum as a Tool to Evaluate Anti Inflammatory Agents in Patients with Cystic Fibrosis; UAB Internal Title:  A Randomized Controlled Trial of anti-Inflammatory Agents in patients with Cystic Fibrosis Using an Assessment of Induced sputum as an Evaluation Tool

CLANCY, JOHN PAUL

EURAND, S.P.A. / PPD DEVELOPMENT, LP

EUR-1008-M

03/17/06

03/16/07

$77,617

A Randomized, Double-Blind, Placebo-Controlled Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients with Cystic Fibrosis and Exocrine Pancreatic Insufficiency

CLANCY, JOHN PAUL

EURAND, S.P.A. / PPD DEVELOPMENT, LP

EUR-1009-M

03/17/06

03/16/07

$5,820

An Open-Label Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Produce (PEP) Microtabs ® in Pediatric Patients with Cystic Fibrosis and Exocrine Pancreatic Insufficiency

CLANCY, JOHN PAUL

THRASHER RESEARCH FUND

______

01/01/05

03/31/07

$189,605

Matrix Metalloproteinases: Mediators of Acute Lung Injury in Children

CLANCY, JOHN PAUL

SALUS PHARMA / CORUS PHARMA

CP-AI-0007

04/25/06

04/24/07

$37,328

A Phase 3, Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreoman Lysinate for Inhalation in Cystic Fibrosis Patients with Pulmonary P. aeruginosa (AIR-CFI)

BEBOK, ZSUZSANNA

PTC THERAPEUTICS, INC.

PTC124-GD-003-CF

01/30/06

04/30/07

$38,973

Morphologic studies following administration of new PTC compounds as oral treatment for nonsense-mediated cystic fibrosis

BEDWELL, DAVID M

NIH-NIGMS

R01GM68854

06/01/03

05/31/07

$1,137,207

Mechanism of Eukaryotic Translation Termination

FU, LIANWU (KARL) / SZTUL, ELIZABETH

NIH-NIDDK

K01 068074

07/01/04

06/30/07

$288,036

Sorting of CFTR for Degradation

CLANCY, JOHN PAUL

INSPIRE PHARMACEUTICALS, INC

08/07/06

08/06/07

$59,991

A Multicenter, Double-Blind, Placebo-controlled Randomized, Efficacy and Safety study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease

BENOS, DALE J

NIH-NIDDK

P50DK53090

09/01/02

08/31/07

$1,080,913

Mechanistic Studies of CF Pathogenesis and CI Secretion - Project 2

BEDWELL, DAVID M

NIH-NIDDK

P50DK53090

09/01/03

08/31/07

$553,906

Mechanistic Studies of CF Pathogenesis and CI Secretion - CF Mouse Core

CLANCY, JOHN PAUL

CYSTIC FIBROSIS FOUNDATION

______

09/01/06

08/31/07

$20,185

Examination of the metabolome of CFBE cell monolayers stably transduced with lentivral cDNAs coding for wt CFTR, and DF508CFTR compared with parental cells expressing endogenous DF508 CFTR

KIRK, KEVIN L

NIH-NIDDK

P50DK53090

09/01/02

08/31/07

$1,080,913

Mechanistic Studies of CF Pathogenesis and CI Secretion - Project 1

SCHWIEBERT, ERIK M

NIH-NIDDK

P50DK53090

09/01/02

08/31/07

$218,633

Mechanistic Studies of CF Pathogenesis and CI Secretion - Core B

SORSCHER, ERIC J

NIH-NIDDK

P50DK53090

09/01/02

08/31/07

$216,493

Mechanistic Studies of CF Pathogenesis and CI Secretion - Core C

BEDWELL, DAVID M

NIH-NIDDK

P50DK53090

09/01/02

08/31/07

$1,080,913

Mechanistic Studies of CF Pathogenesis and CI Secretion - Project 3

CLANCY, JOHN PAUL

PTC THERAPEUTICS / CHILDREN'S HOSPITAL AND REGIONAL MEDICAL CENTER

PTC124-GD-003-CF

09/21/05

09/30/07

$215,050

A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis

GUTIERREZ, HECTOR H

ALABAMA DEPARTMENT OF PUBLIC HEALTH

C70119154

05/01/07

09/30/07

$23,285

Cystic Fibrosis Screening for Newborn Infants

CLANCY, JOHN PAUL

CYSTIC FIBROSIS FOUNDATION / UNIVERSITY OF NORTH CAROLINA CHAPEL HILL

223265

05/07/04

12/01/07

$3,800

Genetic Modifiers in Cystic Fibrosis Lung Disease

GUTIERREZ, HECTOR H

GENENTECH, INC.

Z3877G

04/01/07

03/31/08

$28,462

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme ® Withdrawal on Exercise Tolerance in Cystic Fibrosis Patients

ROWE, STEVEN M

NOVARTIS PHARMACEUTICALS CORPORATION

QAU145A2201

06/11/07

04/08/08

$174,693

A two-part, randomized, double-blind, placebo-controlled, ascending single-dose, adaptive study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of QAU145 administered via a nasal spray pump to patients with cystic fibrosis

CLANCY, JOHN PAUL

CHILDREN'S HOSPITAL & REGIONAL MEDICAL CENTER

412380260101-UAB

07/01/07

06/30/08

$2,430

Antimicrobial resistance in sputum obtained from patients with cystic fibrosis (CF)

BROUILLETTE, CHRISTIE

UAB RESEARCH FOUNDATION

______

08/02/06

09/23/08

$33,469

Testing of SGX/CFFT Proteins and Ligands

FALANY, CHARLES NAPOLEON

CYSTIC FIBROSIS RESEARCH, INC.

______

09/01/06

09/30/08

$120,000

Estrogen Sulfation in the Dysregulation of Hepatocyte Growth Hormone Signaling in Cystic Fibrosis

GUTIERREZ, HECTOR H

ALABAMA DEPARTMENT OF PUBLIC HEALTH

C80117017

10/01/07

09/30/08

$68,379

Cystic Fibrosis Screening for Newborn Infants

CLANCY, JOHN PAUL

VERTEX PHARMACEUTICALS, INC.

______

10/01/07

09/30/08

$20,313

Detection of CFTR in Airway Cells from CF Patients

JI, HONG-LONG / MATALON, SADIS

NIH-NHLBI

R01HL87017

01/01/07

01/31/09

$171,684

Regulation of Epithelial Sodium channels by cGMP

ROWE, STEVEN M

CYSTIC FIBROSIS FOUNDATION

ROWE08AO

02/01/08

01/31/09

$2,700

Examination of the Metabolome of CF and non-CF Tissues from Nasal Polyps

CLANCY, JOHN PAUL

GILEAD SCIENCES, INC.

CP-AI-0006

02/01/07

01/31/09

$45,503

A Phase 3, Open-Label, Follow-on Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3)

BEDWELL, DAVID M

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

______

03/01/08

02/28/09

$20,000

Assay of Aminoglycosides in a CF Mouse Model

CLANCY, JOHN PAUL

KALOBIOS PHARMACEUTICALS, INC.

KB001-03

03/01/08

02/28/09

$35,604

A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose Escalation Study of KB001-Cystic Fibrosis Patients Infected with Pseudomonas Aeruginosa

GUTIERREZ, HECTOR H

UNIVERSITY OF MASSACHUSETTS (WORCHESTER)

337890

07/01/08

02/28/09

$4,000

The Effect of Formula Fortified with Docosahexaenoic Acid (DHA) on Infants with Cystic Fibrosis

GUTIERREZ, HECTOR H

Cystic Fibrosis Foundation Therapeutics, Inc./Children's Hospital & Regional Medical Center

EPIC002 (SCHEDULE 4.0)

11/11/04

03/31/09

$65,649

The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquistion and Early Anti-Pseudomonal Treatment in Children with CF

GUTIERREZ, HECTOR H

CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.

EPIC001 (SCHEDULE 3.0)

11/11/04

03/31/09

$40,357

Efficacy and Safety of Intermittent Animicrobial Therapy for the Treatment of the New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients with Cystic Fibrosis

CLANCY, JOHN PAUL

CYSTIC FIBROSIS FOUNDATION

CLANCY06A0

05/01/06

04/30/09

$390,494

Detection Of Airway CFTR Expression, Localization, and Activity In CF Patients.

ROWE, STEVEN M

NIH-NIDDK

P30DK72482

05/01/07

04/30/09

$86,252

Pilot:  Role of Flavonoids in CFTR Biogenesis and Activation

ROWE, STEVEN M

VERTEX PHARMACEUTICALS, INC. / PPD DEVELOPMENT, LLC.

VX06-770-101

05/04/07

05/03/09

$77,686

A Phase II study of VX-770 in CF Subjects harboring G551D and other surface localized CFTR mutations

YOTHER, JANET L

NIH-NHLBI

T32HL07553

07/01/03

06/30/09

$1,671,051

Basic Mechanisms in Lung Diseases

HAGOOD, JAMES

HRSA

T72MC00001

07/01/05

06/30/09

$1,352,427

Pediatric Pulmonary Center

GUIMBELLOT, JENNIFER

NIH-NIEMS

F30ES14987

07/15/06

07/14/09

$96,762

Effects of Ozone on CFTR Expression and HIF Signaling

BENOS, DALE J

NIH-NIDDK

R01DK37206

08/01/03

07/31/09

$1,678,397

Sodium Entry Into Amiloride-Sensitive Epithelia

CLANCY, JOHN PAUL

TRANSAVE, INC.

TR02-106

09/30/07

08/30/09

$73,023

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (Arikace), in Cystic Fibrosis Patients

GUTIERREZ, HECTOR H

ALABAMA DEPARTMENT OF PUBLIC HEALTH

C90118098

10/01/08

09/30/09

$68,379

Cystic Fibrosis Screening for Newborn Infants

MATALON, SADIS

NIH-NHLBI

R01HL75540

12/15/04

11/30/09

$1,406,668

Nitric Oxide Modulation of CFTR Expression and Function

COLLAWN, JAMES F

CYSTIC FIBROSIS FOUNDATION

COLLAW08PO

12/01/08

11/30/09

$75,000

Cell Biology of CFTR in Polarized Epithelia

CLANCY, JOHN PAUL

INSPIRE PHARMACEUTICALS, INC

08-110

05/28/08

12/31/09

$55,685

A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV1>= 75% Predicted

GUTIERREZ, HECTOR H

CYSTIC FIBROSIS FOUNDATION

GUTIER09QI0

01/01/09

12/31/09

$27,000

Early Recognition and intervention for Acute Pulmonary Exacerbation in CF

ROWE, STEVEN M

VERTEX PHARMACEUTICALS, INC.

VX08-809-101

01/01/09

12/31/09

$92,906

NPD Overreading Services for Clinical Trial Entitled "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the F508-CFTR Gene Mutation"

BERDIEV, BAKHROM K

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION

______

03/01/07

02/28/10

$216,000

Fluorescence Lifetime-Resolved Imaging: Nanoscale Mapping of Dynamic Cellular Events (Pursues CFTR/ENaC Interactions)

HARTMAN IV, JOHN L.

COLUMBIA UNIVERSITY / CYSTIC FIBROSIS FOUNDATION

MILLER08

04/01/08

03/31/10

$94,400

Systematic Genetic and Biochemical Analysis of ER Quality Control (Designed to determine cellular targets for ΔF508 correction)

SORSCHER, ERIC J

NIH-NIDDK

P30DK72482

05/01/09

04/30/10

$66,510

UAB CF Research and Translation Core Center - NIDDK Equipment Supplement

CLANCY, JOHN PAUL

             and

 ROWE, STEVEN M

CYSTIC FIBROSIS FOUNDATION

CLANCY05Y2

01/01/06

04/30/11

$642,688

UAB Cystic Fibrosis National NPD Reading Resource Center Core

CLANCY, JOHN PAUL

CYSTIC FIBROSIS FOUNDATION

41339119.032

06/01/09

05/31/10

$39,700

A Multi-Center, Phase IIB, Randomized, Placebo-Controlled, Double-Blind Study of The Effects of N-Acetylcysteine of Redox Changes and Lung Inflammation in Cystic Fibrosis Patients (NAC40630)

 PYLE, LOUISA

NIH

F30HL096389

06/22/09

06/21/11

$33,450

Potentiation of Mutant CFTR Activity

WOODWORTH, BRADFORD

AMERICAN ACADEMY OF OTOLARYNGOLOGY

______

07/01/09

06/30/10

$25,000

Novel Flavonoid Compounds for Cystic Fibrosis Chronic Rhinosinusitis

FU, LIANWU (KARL)

AMERICAN LUNG ASSOCIATION

______

07/01/08

06/30/10

$75,200

Regulation of the Degradation of Cystic Fibrosis Transmembrane Conductance Regulator under Cystic Fibrosis Conditions

GUTIERREZ, HECTOR H

Cystic Fibrosis Foundation

C001-06

07/01/04

06/30/10

$773,166

Cystic Fibrosis Center for Care, Teaching and Research

CLANCY, JOHN PAUL

DHHS - HEALTH RESOURCES AND SERVICES ADMINISTRATION (MATERNAL AND CHILD HEALTH BUREAU)

6T72MC00001-19-01

07/01/09

06/30/10

$332,095

Pediatric Pulmonary Center

ROWE, STEVEN M

CYSTIC FIBROSIS FOUNDATION

FREDER09B0

07/01/09

06/30/10

$48,000

CFF Clinical Fellowship

CLANCY, JOHN PAUL

INSPIRE PHARMACEUTICALS, INC

08-114

07/13/09

07/12/10

$36,169

Open-Label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease

BENOS, DALE J

NIH-NIDDK

R56DK37206

08/17/09

07/31/10

$362,500

Sodium Entry Into Amiloride-Sensitive Epithelia

BERDIEV, BAKHROM K

NIH - NHLBI

R21HL085112

09/01/08

07/31/10

$412,500

Regulation of Epithelial Sodium Channel by CFTR Chloride Channel

DELUCAS, LAWRENCE J.

CYSTIC FIBROSIS FOUNDATION

DELUCA05XXO

08/01/05

07/31/12

$2,063,100

Crystallization and Structure Determination of Full-Length CFTR Protein

ROWE, STEVEN M

PTC THERAPEUTICS, INC.

PTC124-GD-009-CF

08/05/09

12/31/11

$243,755

Nasal PD Central Reading Services for Clinical Trial Entitled: A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis

ROWE, STEVEN M

CYSTIC FIBROSIS FOUNDATION

ROWE08XX0

09/01/08

08/31/10

$25,000

CFTR Activity of Novel F508 Corrector Agents

BROUILLETTE, CHRISTIE

CYSTIC FIBROSIS FOUNDATION

BROUIL08XXO

09/01/08

08/31/12

$175,755

Expression and purification of CFTR Domain Constructs

CHUNG, WOOK JOON

NIH-NINDS

R21NS067693

09/25/09

08/31/10

$208,358

A Novel HTS Cell-Based Imaging Assay to Identify Chemical Correctors for F508-CFTR Defects

SCHWIEBERT, ERIK M

NIH-NIDDK

R43 DK084658

09/30/09

08/31/10

$308,000

CF Corrector Ligands Discovered in CF Human Airway Cells

DELUCAS, LAWRENCE J

NIH - NIGMS

R01GM081799

09/15/08

08/31/10

$869,148

Innovative Methods for Membrane Protein Expression and Crystallization

ROWE, STEVEN M

CYSTIC FIBROSIS FOUNDATION

ROWE09CS0

10/01/09

09/30/10

$56,841

Special Consultant for Translational Science

BROUILLETTE, CHRISTIE

CYSTIC FIBROSIS FOUNDATION

BROUIL07XX0

11/01/07

   10/31/12

$561,202

Recombinant CFTR:  Cooperativity of Structural Domains

CLANCY, JOHN PAUL

KAUL PEDIATRIC RESEARCH INSTITUTE

______

01/01/08

12/31/10

$60,000

Matrix Metalloproteinase-9 in Pediatric RSV-Induced Respiratory Failure

ROWE, STEVEN M and

YOUNG, K. RANDALL

CYSTIC FIBROSIS FOUNDATION

 CLANCY09Y0

01/01/07

12/31/11

$1,021,368

UAB Cystic Foundation Therapeutic Development Center

ROWE, STEVEN M

MASSACHUSETTS GENERAL HOSPITAL

323840

01/01/08

12/31/10

$31,900

Development of Optical Coherence Tomography for Measures of Mucociliary Clearance

CLANCY, JOHN PAUL

VERTEX PHARMACEUTICALS, INC.

VX06-770-101

08/29/07

12/31/10

$47,940

Nasal PD Central Reading Services for Study Entitled:  A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 t

KIRK, KEVIN L

NIH - NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

R56DK056796

02/01/10

01/31/11

$219,750

New Paradigms of CFTR Regulation

KIRK, KEVIN L

NIH-NIDDK

R01DK56796

09/01/05

01/31/11

$1,149,353

New Paradigms of CFTR Regulation

ROWE, STEVEN M

CYSTIC FIBROSIS FOUNDATION

ROWE09XX0

03/01/09

02/28/11

$50,000

Ussing Chamber Studies to Characterize CFTR Modulators

BEDWELL, DAVID M

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

______

03/01/10

02/28/11

$20,000

Assay of Aminoglycosides in a CF Mouse Model

CLANCY, JOHN PAUL

VERTEX PHARMACEUTICALS, INC.

VX08-809-101

03/01/09

02/28/11

$98,070

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the F508-CFTR Gene Mutation

ROWE, STEVEN M

PTC THERAPEUTICS, INC.

PTC124-GD-009-CF

03/01/09

02/28/11

$113,422

A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis

GAGGAR, AMIT

CYSTIC FIBROSIS FOUNDATION

GAGGAR07AO

04/01/07

03/31/11

$254,604

Implications of cross-protease dysregulation in CF

CLANCY, JOHN PAUL

GILEAD SCIENCES, INC.

EA-US-205-0111

05/21/08

05/20/11

$4,000

Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disease Progression

ROWE, STEVEN M

NIH-NIDDK

R03DK084110

08/25/09

06/30/11

$73,188

Mechanisms Underlying Protein Repair of CFTR Nonsense Mutations

BLALOCK, J EDWIN

NIH - NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

R01HL087824

07/01/09

06/30/11

$411,364

Therapeutics for Chronic Lung Disease: New Antagonists of PGP, Chemokines and CXCR

GUTIERREZ, HECTOR H

VERTEX PHARMACEUTICALS, INC.

VX-08-770-103

07/10/09

07/09/11

$104,765

A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 to 11Years with Cystic Fibrosis and the G551D Mutation

ROWE, STEVEN M

VERTEX PHARMACEUTICALS, INC.

VX-08-770-102

07/10/09

07/09/11

$119,045

A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX 770 in Subjects with Cystic Fibrosis and the G551D Mutation

STEELE, CHAD

NIH-UNIVERSITY OF PITTSBURGH

______

08/10/09

07/31/11

$109,627

Immune Tolerance and Inflammation in ABPA in Patients with Cystic Fibrosis

SORSCHER, ERIC J

CYSTIC FIBROSIS FOUNDATION

SORSCH05X0

09/01/06

08/31/12

$2,019,168

New Reagents for Understanding and Overcoming the Delta-F508 Mutation

GUTIERREZ, HECTOR H

NIH-NIDDK

P30 DK072482

09/12/09

08/31/11

$204,401

UAB CF Research and Translation Core Center - Pilot Supplement

ROWE, STEVEN M

NIH-NCRR

UL1RR025777

09/17/09

03/31/12

$500,000

UAB Center for Clinical and Translational Science (CCTS); (ARRA Supplement (to conduct a multicenter trial of quercetin as an activator of mutant CFTR)

GUTIERREZ, HECTOR H

ALABAMA DEPARTMENT OF PUBLIC HEALTH

C00113045

10/01/09

09/30/11

$136,758

Cystic Fibrosis Screening for Newborn Infants

BEDWELL, DAVID M

NIH - NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

R01GM068854-07S1

12/01/07

11/30/11

$1,038,039

Mechanism of Eukaryotic Translation Termination (Basic studies to understand mechanism of CFTR truncation alleles)

CLANCY, JOHN PAUL

KAUL PEDIATRIC RESEARCH INSTITUTE

______

02/01/10

01/31/12

$50,000

Developing GI Outcome Measures for CFTR Modulator Trials in Young CF Patients

HARRIS, WILLIAM THOMAS

KAUL PEDIATRIC RESEARCH INSTITUTE

______

02/01/10

01/31/12

$30,000

Myofibroblast proliferation in cystic fibrosis:  a novel mechanism of disease modification

YOUNG, K. RANDALL

GLAXOSMITHKLINE

CF 2110399

02/08/10

02/07/12

$33,239

A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis (CF 2110399)

ROWE, STEVEN M

VERTEX PHARMACEUTICALS, INC.

______

03/01/09

02/28/12

awarded

Bidirectional Transfer of Isolated Primary Airway Cells Obtained from Lung and Sinus Explants

BEDWELL, DAVID M

NIH - NIDDK

P30DK72482

05/01/07

04/30/12

$619,962

UAB CF Research and Translation Core Center - Mouse Models

KIRK, KEVIN L

NIH-NIDDK

P30DK72482

05/01/07

04/30/12

$581,639

Core A:  Cell Model and Assay Core

SORSCHER, ERIC J

NIH-NIDDK

P30DK72482

05/01/07

04/30/12

$752,209

UAB CF Research and Translation Core Center - Administrative Core

ROWE, STEVEN M

NIH - NIDDK

P30DK72482

05/01/07

04/30/12

$389,146

UAB CF Research and Translation Core Center - Clinical Core

ROWE, STEVEN M

CYSTIC FIBROSIS FOUNDATION

 CLANCY 05Y2

01/01/11

04/30/12

$224,062

UAB Center for CFTR Detection

CORMET-BOYAKA, ESTELLE

AMERICAN LUNG ASSOCIATION

______

07/01/10

06/30/12

$160,000

Cadmium Alters Regulation of Lung Function via Ion Transport and Inflammatory Cytokines

KIRK, KEVIN L

NIH-NHLBI

R01HL58341

07/01/07

06/30/12

$978,750

Regulation of CFTR by Syntaxin and N-sec 1 Isoforms

CLINES, GREGORY A.

NIH-NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

R21 AR056826

07/01/10

06/30/12

$156,024

CF Bone Disease:  Convergence of CFTR and PTH Signaling

BLALOCK, J EDWIN

ALBANY MEDICAL COLLEGE

SC07-10-001

08/15/08

07/31/12

$188,500

MMP-9 Modulation as an Immunotherapeutic Intervention for Respiratory Infections

BEBOK, ZSUZSANNA

NIH-NHLBI

R01HL76587

05/01/04

03/31/13

$1,894,192

CFTR Biogenesis and Function in Epithelia

CHRISTIAN, BECKY

NIH-NCRR

UL1RR025777

05/01/11

04/30/13

$30,000

Making Connections: Improving Quality of Life in Adolescents with Cystic Fibrosis

PIAZZA, GARY

CYSTIC FIBROSIS FOUNDATION

R464-CR07

06/01/11

06/30/13

$72,000

Spectral domain optical coherence tomography for the functional characterization of ion transport modulators

JACKSON, PATRICIA

CYSTIC FIBROSIS FOUNDATION

R464-CR07

07/01/11

06/30/13

$72,000

Modulation of Small Matrikines by Reactive Aldehydes in CF

BARNES, STEPHEN

CYSTIC FIBROSIS FOUNDATION

R464-CR07

07/01/11

06/30/13

$72,000

Analysis of CFTR Post Translational Modification by Mass Spectrometry

CLANCY, JOHN PAUL

CHILDREN'S HOSPITAL & REGIONAL MEDICAL CENTER

346609

07/01/08

12/31/13

$9,164

CF Therapeutics Development Network Individual Project Schedule #6.0

BLALOCK, J. EDWIN

NIH-NHLBI

R01HL077783

04/01/06

03/31/14

$1,789,648

A New Pathway for Neutrophil-Induced Airway Inflammation

GUTIERREZ, HECTOR H

CHILDREN'S HOSPITAL & REGIONAL MEDICAL CENTER

41339135.032O

04/01/09

03/31/14

$17,694

The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF

COLLAWN, JAMES F

NIH-NIDDK

R01DK60065

12/20/02

04/30/14

$1,790,554

Cell Biology of CFTR in Polarized Epithelia

ABRAHAM, EDWARD

NIH-NHLBI

R01GM087748

06/01/09

05/31/14

$303,642

HMGB1 and Neutrophil Efferocytosis

WANG, GUANGYU

AMERICAN HEART ASSOCIATION

______

07/01/10

06/30/14

$77,000

Inhibition Mechanisms of the Regulatory Domain in the Cystic Fibrosis Transmembrane Conductance Regulator

WOODWORTH, BRADFORD

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION

______

12/01/07

12/01/14

$150,000

UAHSF General Endowment Fund Scholar Award for Studies of CFTR in Sinonasal Epithelial Cells

DELUCAS, LAWRENCE J

NIH - NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

R01GM095639

09/30/10

07/31/14

$300,000

Production & Crystallization of Membrane Protein for 3D Structure (includes studies of CFTR)

KIRK, KEVIN L

NIH - NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

R01DK056796

02/01/11

01/31/15

$318,638

New Paradigms of CFTR Regulation

GAGGAR, AMIT

NIH-NHLBI

R01HL102371

07/01/10

05/31/15

$377,902

A Novel Proteolytic System of Pulmonary Inflammation.

HOOVER, WYNTON C

DHHS - HEALTH RESOURCES AND SERVICES ADMINISTRATION (MATERNAL AND CHILD HEALTH BUREAU)

T72MC00001

07/01/10

06/30/15

$365,000

UAB Pediatric Pulmonary Center

SORSCHER, ERIC J

CYSTIC FIBROSIS FOUNDATION

R464-CR11

07/01/11

06/30/15

$284,000

Research Development Program - Component II

FULLER, CATHERINE M

NIH-NIDDK

R01DK037206

08/01/10

07/31/15

$366,250

Sodium Entry into Amiloride-Sensitive Epithelia

ROWE, STEVEN M

NIH/NATIONAL HEART, LUNG, BLOOD INSTITUTE

R01HL405487

02/15/11

01/31/16

$367,550

Molecular Pathogenesis and Phenotype of Acquired CFTR dysfunction in COPD

WOODWORTH, BRADFORD

NIH - NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH

K08DE021426

03/01/11

02/29/16

$133,596

Chloride Secretagogues for Acquired CFTR Dysfunction in Chronic Rhinosinusitis

BEDWELL, DAVID M

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

R01 GM094792 (subcontract)

04/01/11

03/31/16

$134,677

Tuning aminoglycosides for treatment of genetic diseases

Total for the above awarded grants =

$46,033,877

consists of:

NIH funding =

$28,814,579

62.59%

CFF/CFFT funding =

$10,001,238

21.73%

All other sponsors =

$7,218,060

15.68%

$46,033,877

100.00%

Interdisciplinary Departments represented by the above Principle Investigators:

Anesthesiology

(Ji, Matalon)

Nursing

(Christian)

Cell Biology

(Bebok, Berdiev, Collawn, Fu, Sztul)

Optometry

(Delucas)

Chemistry

(Brouillette)

Pediatrics

(Clancy, Gutierrez, Harris)

Genetics

(Guimbellot, Hartman, Pyle)

Pharmacology

(Falany)

Medicine

(Blalock, Clines, Gaggar,

Physiology & Biophysics

(Benos, Kirk, Schwiebert)

Liu, Rowe, Sorscher, Steele)

Public Health

(Fannuchi)

Microbiology

(Bedwell, Yother)

Surgery

(Woodworth)

Neurobiology

(Chung)